Evaluation of AAV8 encoding mouse <i>Vldlr</i> or mouse <i>Ldlr</i> in Ldlr-/-Apobec1-/- Mice.

<p>(A) Plasma cholesterol levels in <i>Ldlr-/-Apobec1-/-</i> mice after treatment with AAV8.TBG.<i>mVLDLR</i> or AAV8.TBG.<i>mLDLR</i> (n = 5 animals per dose group). Each point represents mean ± s.d. *P<0.05, **P<0.01, ***P<0.001 (B and C) Pooled mouse plasma from AAV-injected <i>Ldlr-/-Apobec1-/-</i> (n = 5) were analyzed by FPLC fractionation and the cholesterol content of each fraction was determined. (B) Lipoprotein profile of animals injected with 1×10∧12 GC of vector 28 days after treatment. (C) Lipoprotein profile of animals injected with 3×10∧11 GC of vector 28 days after treatment. (D) Plasma ALT levels in <i>Ldlr-/-Apobec1-/-</i> mice after treatment with AAV8.TBG.<i>mVLDLR</i> or AAV.TBG.<i>mLDLR</i> (n = 5 animals per dose group). Each point represents mean ± s.d. At all time points and doses examined, no significant differences in ALT were detected between AAV8.TBG.<i>mLDLR</i> and AAV8.TBG.<i>mVLDLR</i>.